LLY

886.38

+0.13%↑

UNH

590.76

-0.37%↓

NVO

114.93

-0.16%↓

JNJ

160.38

-0.07%↓

ABBV

194.31

-0.59%↓

LLY

886.38

+0.13%↑

UNH

590.76

-0.37%↓

NVO

114.93

-0.16%↓

JNJ

160.38

-0.07%↓

ABBV

194.31

-0.59%↓

LLY

886.38

+0.13%↑

UNH

590.76

-0.37%↓

NVO

114.93

-0.16%↓

JNJ

160.38

-0.07%↓

ABBV

194.31

-0.59%↓

LLY

886.38

+0.13%↑

UNH

590.76

-0.37%↓

NVO

114.93

-0.16%↓

JNJ

160.38

-0.07%↓

ABBV

194.31

-0.59%↓

LLY

886.38

+0.13%↑

UNH

590.76

-0.37%↓

NVO

114.93

-0.16%↓

JNJ

160.38

-0.07%↓

ABBV

194.31

-0.59%↓

Home・Stock List・Bio-Techne Corp

Bio-Techne Corp

Closed

Sector Healthcare

74.79 1.01

Buy Sell

Overview

Share price change

24h

Current

Min

74.03

Max

74.82

Key metrics
By Trading Economics
Income	-8.5M 41M
Sales	-303B 306M
P/E Sector Avg	50.64 113.916
EPS	0.49
Profit margin	13.26
EBITDA	92M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+8.71 upside

Dividends
By Dow Jones
Next Earnings	29 Oct 2024
Next Dividend date	22 Nov 2024
Next Ex Dividend date	7 Nov 2024

Market Stats
By TradingEconomics
Market Cap	-176M 12B
Previous open	73.78
Previous close	74.79

News Sentiment

By Acuity

77%

23%

346 / 366 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

73.89 / 77.38 Support & Resistance

Bio-Techne Corp Chart

Past performance is not a reliable indicator of future results.

Related News

6 Oct 2024, 23:48 UTC

Acquisitions, Mergers, Takeovers

Rio Tinto in Talks to Acquire Arcadium Lithium -- Update

6 Oct 2024, 22:14 UTC

Acquisitions, Mergers, Takeovers

Rio Tinto in Talks to Acquire Arcadium Lithium

7 Oct 2024, 00:00 UTC

Acquisitions, Mergers, Takeovers

Starboard Has Approached Former Pfizer Execs to Help its Efforts, Sources Say -- WSJ

7 Oct 2024, 00:00 UTC

Acquisitions, Mergers, Takeovers

Activist Starboard Value Has Roughly $1B Stake in Pfizer, Sources Say -- WSJ

7 Oct 2024, 00:00 UTC

Acquisitions, Mergers, Takeovers

Starboard Wants Drugmaker to Make Changes to Improve Performance, Sources Say -- WSJ

7 Oct 2024, 00:00 UTC

Acquisitions, Mergers, Takeovers

Activist Starboard Value Takes $1 Billion Stake in Pfizer -- WSJ

6 Oct 2024, 21:48 UTC

Acquisitions, Mergers, Takeovers

Arcadium Lithium Says Won't Comment Further Unless News to Share

6 Oct 2024, 21:47 UTC

Acquisitions, Mergers, Takeovers

Arcadium Lithium Says Remains Focused on Strategic Vision, Growth Plans

6 Oct 2024, 21:45 UTC

Acquisitions, Mergers, Takeovers

Rio Tinto: Confirms Has Made Approach to Acquire Arcadium Lithium

6 Oct 2024, 21:45 UTC

Acquisitions, Mergers, Takeovers

Rio Tinto: Approach is Non-Binding, No Certainty Any Deal Will be Agreed

6 Oct 2024, 21:45 UTC

Acquisitions, Mergers, Takeovers

Rio Tinto: Won't Comment Further Unless Update Appropriate

6 Oct 2024, 12:30 UTC

Top News

Earnings

Microsoft's AI Story Is Getting Complicated -- Heard on the Street -- WSJ

6 Oct 2024, 09:30 UTC

Earnings

Corporate Insiders Are Sitting Out the 2024 Stock-Market Rally -- WSJ

6 Oct 2024, 01:00 UTC

Earnings

Google's Grip on Search Slips as TikTok and AI Startup Mount Challenge -- WSJ

5 Oct 2024, 10:00 UTC

Top News

How Long Can the U.S. Economy's 'Goldilocks' Moment Last? -- Heard on the Street -- WSJ

4 Oct 2024, 23:14 UTC

Acquisitions, Mergers, Takeovers

There's a Bear in the Art Market -- and Here Are the Numbers -- Barrons.com

4 Oct 2024, 21:14 UTC

Earnings

The Score: Stellantis, Nike, Spirit Airlines and More Stocks That Defined the Week -- WSJ

4 Oct 2024, 20:43 UTC

Top News

GM Halts Production at Factories Due to Hurricane Helene -- Barrons.com

4 Oct 2024, 20:36 UTC

Top News

Blowout Jobs Report Boosts Shares, Hits Bonds -- WSJ

4 Oct 2024, 20:33 UTC

Top News

American Consumer Spending Boosts September Hiring -- WSJ

4 Oct 2024, 20:31 UTC

Top News

Jeep Parent Stellantis Taking 'Drastic Measures' to Conserve Cash -- 4th Update

4 Oct 2024, 20:26 UTC

Top News

U.S. Economy Added 254,000 Jobs in September -- 5th Update

4 Oct 2024, 20:05 UTC

Top News

Acquisitions, Mergers, Takeovers

Activist Mantle Ridge Has Over $1 Billion Stake in Air Products -- WSJ

4 Oct 2024, 20:05 UTC

Acquisitions, Mergers, Takeovers

Mantle Ridge Plans to Push for CEO Succession Planning, Among Other Things, Sources Say -- WSJ

4 Oct 2024, 20:05 UTC

Acquisitions, Mergers, Takeovers

Activist Mantle Ridge Has Over $1B Stake in Air Products, Sources Say -- WSJ

4 Oct 2024, 19:45 UTC

Market Talk

Natural Gas Tumbles to Close Week -- Market Talk

4 Oct 2024, 19:30 UTC

Market Talk

Oil Posts Biggest Weekly Gain in Over a Year -- Market Talk

4 Oct 2024, 19:04 UTC

Top News

Jeep Parent Stellantis Taking 'Drastic Measures' to Conserve Cash -- 3rd Update

4 Oct 2024, 18:33 UTC

Top News

Jeep Parent Stellantis Taking 'Drastic Measures' to Conserve Cash -- 2nd Update

4 Oct 2024, 18:21 UTC

Top News

Blowout Jobs Report Boosts Shares, Hits Bonds -- Update

Peer Comparison

Price change

Bio-Techne Corp Forecast

Price Target

By TipRanks

8.71% upside

12 Months Forecast

Average 81.29 USD 8.71%

High 95 USD

Low 65 USD

Based on 7 Wall Street analysts offering 12 month price targets forBio-Techne Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Bio-Techne Corp - Dist in the past 3 months.

Technical Score

By Trading Central

73.89 / 77.38Support & Resistance

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

346 / 366 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Bio-Techne Corp

Bio-Techne Corporation is a developer, manufacturer, and seller of life science reagents, instruments and services for the research, diagnostics, and bioprocessing markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.